Megan Hoopes1, Teresa Schmidt1, Nathalie Huguet2, Kerri Winters-Stone3,4, Heather Angier2, Miguel Marino2,5, Jackilen Shannon3,5, Jennifer DeVoe2. 1. OCHIN Inc, Portland, Oregon. 2. Department of Family Medicine, Oregon Health and Science University, Portland, Oregon. 3. Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. 4. School of Nursing, Oregon Health and Science University, Portland, Oregon. 5. School of Public Health, Oregon Health and Science University-Portland State University, Portland, Oregon.
Abstract
BACKGROUND: Primary care providers must understand the use patterns, clinical complexity, and primary care needs of cancer survivors to provide quality health care services. However, to the authors' knowledge, little is known regarding the prevalence and health care needs of this growing population, particularly in safety net settings. METHODS: The authors identified adults with a history of cancer documented in primary care electronic health records within a network of community health centers (CHCs) in 19 states. The authors estimated cancer history prevalence among >1.2 million patients and compared sex-specific site distributions with national estimates. Each survivor was matched to 3 patients without cancer from the same set of clinics. The demographic characteristics, primary care use, and comorbidity burden then were compared between the 2 groups, assessing differences with absolute standardized mean differences (ASMDs). ASMD values >0.1 denote meaningful differences between groups. Generalized estimating equations yielded adjusted odds ratios (aORs) for select indicators. RESULTS: A total of 40,266 cancer survivors were identified (prevalence of 3.0% of adult CHC patients). Compared with matched cancer-free patients, a higher percentage of survivors had ≥6 primary care visits across 3 years (62% vs 48%) and were insured (83% vs 74%) (ASMD, >0.1 for both). Cancer survivors had excess medical complexity, including a higher prevalence of depression, asthma/chronic obstructive pulmonary disease, and liver disease (ASMD, >0.1 for all). Survivors had higher odds of any opioid prescription (aOR, 1.23; 95% CI, 1.19-1.27) and chronic opioid therapy (aOR, 1.27; 95% CI, 1.23-1.32) compared with matched controls (P < .001 for all). CONCLUSIONS: Identifying cancer survivors and understanding their patterns of utilization and physical and mental comorbidities present an opportunity to tailor primary health care services to this population.
BACKGROUND: Primary care providers must understand the use patterns, clinical complexity, and primary care needs of cancer survivors to provide quality health care services. However, to the authors' knowledge, little is known regarding the prevalence and health care needs of this growing population, particularly in safety net settings. METHODS: The authors identified adults with a history of cancer documented in primary care electronic health records within a network of community health centers (CHCs) in 19 states. The authors estimated cancer history prevalence among >1.2 million patients and compared sex-specific site distributions with national estimates. Each survivor was matched to 3 patients without cancer from the same set of clinics. The demographic characteristics, primary care use, and comorbidity burden then were compared between the 2 groups, assessing differences with absolute standardized mean differences (ASMDs). ASMD values >0.1 denote meaningful differences between groups. Generalized estimating equations yielded adjusted odds ratios (aORs) for select indicators. RESULTS: A total of 40,266 cancer survivors were identified (prevalence of 3.0% of adult CHCpatients). Compared with matched cancer-free patients, a higher percentage of survivors had ≥6 primary care visits across 3 years (62% vs 48%) and were insured (83% vs 74%) (ASMD, >0.1 for both). Cancer survivors had excess medical complexity, including a higher prevalence of depression, asthma/chronic obstructive pulmonary disease, and liver disease (ASMD, >0.1 for all). Survivors had higher odds of any opioid prescription (aOR, 1.23; 95% CI, 1.19-1.27) and chronic opioid therapy (aOR, 1.27; 95% CI, 1.23-1.32) compared with matched controls (P < .001 for all). CONCLUSIONS: Identifying cancer survivors and understanding their patterns of utilization and physical and mental comorbidities present an opportunity to tailor primary health care services to this population.
Authors: Charles L Shapiro; Mary S McCabe; Karen L Syrjala; Debra Friedman; Linda A Jacobs; Patricia A Ganz; Lisa Diller; Marci Campell; Kathryn Orcena; Alfred C Marcus Journal: J Cancer Surviv Date: 2009-01-24 Impact factor: 4.442
Authors: Mary E Charlson; Robert E Charlson; Janey C Peterson; Spyridon S Marinopoulos; William M Briggs; James P Hollenberg Journal: J Clin Epidemiol Date: 2008-07-10 Impact factor: 6.437
Authors: Ana R Quiñones; Steele H Valenzuela; Nathalie Huguet; Maria Ukhanova; Miguel Marino; Jennifer A Lucas; Jean O'Malley; Teresa D Schmidt; Robert Voss; Katherine Peak; Nathaniel T Warren; John Heintzman Journal: J Gen Intern Med Date: 2022-01-28 Impact factor: 6.473
Authors: Katelyn K Jetelina; Simon Craddock Lee; Quiera S Booker-Nubie; Udoka C Obinwa; Hong Zhu; Michael E Miller; Navid Sadeghi; Umber Dickerson; Bijal A Balasubramanian Journal: J Cancer Surviv Date: 2022-01-05 Impact factor: 4.062
Authors: Heather E Angier; Miguel Marino; Rachel J Springer; Teresa D Schmidt; Nathalie Huguet; Jennifer E DeVoe Journal: Cancer Date: 2020-04-15 Impact factor: 6.860